To compare the effects of oral tofacitinib plus oral puvasol with oral corticosteroids plus oral puvasol in vitiligo patients and also study the side effects of bothe drugs

TO STUDY AND COMPARE THE EFFECTIVENESS OF ORAL TOFACITINIB PLUS ORAL PUVASOL VS ORAL CORTICOSTEROIDS PLUS ORAL PUVASOL IN VITILIGO - A RANDOMIZED CONTROL TRIAL. - NO TRIAL ACRONYM

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069125

Enrollment

Registered

2024-06-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: ORAL TOFACITINIB PLUS ORAL PUVASOL: CONVENTIONAL AGENT FOR VITILIGO TREATMENT Intervention2: TOFACITINIB PLUS ORAL PUVASOL: THIS IS THE NEW DRUG WHICH HAS BEEN ALREADY USED IN TREATMENT

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age more than 18 years 2. Body surface area less than 80% 3. Progressive disease( peak of incidence within 6 months )

Exclusion criteria

Exclusion criteria: 1. Universal vitiligo 2. Pregnant and lactating women 3. Patients undergoing immunosuppressive therapy 4. Patients of leukoderma due to other causes 5. Patients having photosensitivity 6. Patients having malignancy or undergone radiotherapy.

Design outcomes

Primary

Measure	Time frame
Repigmentation in test (18 patients ) and control group (18 patients ) comparing with VASI score at 12 and 24 weeks.Timepoint: 12 and 24 weeks	—

Secondary

Measure	Time frame
Study the side effects of drugs in both the test & control groupTimepoint: 12 & 24 weeks	—

Countries

India

Contacts

Public ContactSUPRIYA BEHERA

SCB MEDICAL COLLEGE AND HOSPITAL, CUTTACK

titoon@rediffmail.com7873144124

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026